King Pharmaceuticals KG Deferred Policy Acquisition Costs, Amortization Expense
Deferred Policy Acquisition Costs, Amortization Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredPolicyAcquisitionCostAmortizationExpense.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's deferred policy acquisition costs, amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's deferred policy acquisition costs, amortization expense?
- King Pharmaceuticals (KG) reported deferred policy acquisition costs, amortization expense of $1.47M in Q1 2026.
- What does deferred policy acquisition costs, amortization expense mean?
- The periodic expense recognized for the amortization of costs directly associated with acquiring new insurance policies, such as commissions and underwriting fees. These costs are initially capitalized and then expensed over the life of the policy to match revenue recognition. It provides insight into the efficiency of the company's sales and distribution strategy.